- OmniaBio: positioning Ontario to lead in a global biomanufacturing boom. Perspective, page 8, March 24, 2023.
- Canadian life science companies commercializing innovation in Hamilton. Perspective, page 26, March 24, 2023.
- Catamaran Bio, OmniaBio Partner to Advance Allogeneic CAR-NK Cell Therapies. Contract Pharma, March 14, 2023.
- A biomanufacturing site is coming to Canada’s Prince Edward Island. Endpoints News, February 14, 2023.
- Nowhere to grow — Canadian life sciences companies look for lab space. Research Money, January 25, 2023.
- Biggest Names in STEM Fly North For Talent. Site Selection magazine, January 2023 issue.
- HAMILTON HIT AN ALLTIME RECORD FOR BUILDING PERMIT VALUES AT OVER $2.1-BILLION. Perspective, December 12, 2022.
- Cell and Gene Champions Speak Out. The Medicine Maker, December 1, 2022 (2023 Special Supplement).
- Medipost, OmniaBio to enhance cooperation for CDMO business. The Korea Economic Daily, December 1, 2022.
- OmniaBio: Ready for the Global Biomanufacturing Boom. ISCT Telegraft Hub, November 2022 issue.
- Avectas, CCRM and OmniaBio’s Collaboration to Accelerate the Manufacture of Edited iPSCs. Phacilitate website, November 30, 2022.
- Avectas, CCRM & OmniaBio Expand Their Collaboration to Accelerate the Manufacture of Edited iPSCs Using SOLUPORE Technology. Drug Development & Delivery, November 30, 2022.
- Race is on to claim share of biomanufacturing market. Investment Monitor, November 23, 2022.
- Resolution Therapeutics And CCRM Sign Collaboration Agreement To Develop And Scale Up Manufacturing For iPSC-Derived Macrophage Cell Therapies. Outsourced Pharma, November 7, 2022.
- Government Engagement Bodes Well For [Canadian] Life Sciences. MarketScreener, October 26, 2022.
- NGen appuie la fabrication commerciale de thérapies cellulaires et géniques au Canada. CScience, October 11, 2022.
- Innovation and commercialization in Southern Ontario. Synapse Consortium Brochure, Page 20. October 6, 2022.
- NGen invests $10.5 M in Canadian Gov’t Cell-, Gene-Therapy Project. DCAT Value Chain Insights, September 29, 2022.
- The Short Report – September 28, 2022. Research Money, September 28, 2022.
- OmniaBio brings biomanufacturing muscle to Ontario. BIOTECanada Insights, Fall 2022 issue.
- NGen Invests $10.5M to Support Commercial Scale Manufacturing of Cell & Gene Therapies in Canada. Contract Pharma, September 22, 2022.
- CHCH Evening News at 6: OmniaBio and NGen feature. CHCH-TV, September 20, 2022.
- Meet Mitch: The CEO leading Canada’s largest CDMO dedicated to manufacturing for CGTs. Signals blog, September 15, 2022.
- CBRE Helps Launch Game-Changing Biomanufacturing Facility For Hamilton. CBRE website, September 7, 2022.
- OmniaBio shapes the future of regenerative medicine. Invest Ontario website, July 27, 2022.
- Multiplex to deliver McMaster Innovation Park’s flagship OmniaBio B, Canada’s first gene therapy facility. Multiplex Global website, July 19, 2022.
- OmniaBio shares expansion plans with Hamilton investment partners at Collision Conference (with video). Invest in Hamilton website, June 23, 2022.
- A big investment in CCRM’s OmniaBio, feds seek to advance digital charter, forging a new oil sands alliance, launching a climate impact accelerator, and more. Research Money, June 22, 2022.
- OmniaBio, Medipost Ink Acquisition and Investment Deal. Contract Pharma, June 7, 2022.
- Canada aims to get a slice of the growing global market for cell and gene therapies. Toronto Star, May 18, 2022.
- McMaster Innovation Park wants more residential dev. Real Estate News EXchange, May 16, 2022.
- What’s A CDMO And Why Do Biotech Startups Need them? Let’s Ask Canada. Crunchbase News, May 5, 2022.
- Healthcare Is a Cost. But It’s Also a Business Opportunity. Canadian Business, April 26, 2022.
- Gene therapy manufacturing coming to McMaster Innovation Park. The Bay Observer, April 1, 2022.
- Ontario antes up $580M for C&G therapy plant in Hamilton. Endpoints News, April 1, 2022.
- Ontario invests $40 million to grow global life sciences sector at Hamilton’s McMaster Innovation Park. Toronto Star, April 1, 2022
- Ontario invests in $580 million gene and cell therapy facility in Hamilton. CHCH-TV, March 31, 2022.
- New gene- and cell-therapy manufacturing facility to launch in Hamilton with $580-million commitment. The Globe and Mail, March 31, 2022.
- WATCH: Ontario economic development minister to make announcement in Hamilton at 1:30 p.m. CHCH-TV, March 31, 2022.